Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro

Article activity feed

1. 

   ScreenIT

   Jun 5, 2020

   SciScore for 10.1101/2020.03.29.014407: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Cells, virus and antivirals: Vero E6 (Vero C1008, clone E6 – CRL-1586; ATCC) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with non-essential amino acids (NEAA), penicillin/streptomycin (P/S), Hepes buffer and 10% (v/v) Fetal bovine serum (FBS).	Vero C1008 suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)
   A clinical isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489) was isolated and …

   SciScore for 10.1101/2020.03.29.014407: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Cells, virus and antivirals: Vero E6 (Vero C1008, clone E6 – CRL-1586; ATCC) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with non-essential amino acids (NEAA), penicillin/streptomycin (P/S), Hepes buffer and 10% (v/v) Fetal bovine serum (FBS).	Vero C1008 suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)
   A clinical isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489) was isolated and propagated in Vero E6 cells, and viral titer was determined by 50% tissue culture infective dose (TCID50) and plaque assay for confirming the obtained titer.	Vero E6 suggested: None
   Software and Algorithms
   Sentences	Resources
   The quality of raw sequences obtained from MiSeq run was first checked using FastQC (v 0.11.5) (Babraham Bioinformatics).	MiSeq suggested: (A5-miseq, RRID:SCR_012148) FastQC suggested: (FastQC, RRID:SCR_014583)
   The reads were aligned on reference sequence (GISAID accession ID: EPI_ISL_412973) using BWA-mem and rescued using Samtools alignment/Map (v 1.9) and bamtoFastq.	BWA-mem suggested: (Sniffles, RRID:SCR_017619) Samtools suggested: (SAMTOOLS, RRID:SCR_002105)
   Finally, the contigs were generated using SPAdes (v 3.12.0).	SPAdes suggested: (SPAdes, RRID:SCR_000131)
   Then, two-way ANOVA and Tukey’s multiple comparisons test were performed for the evaluation of Ct differences (GraphPad Prism 8).	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
   • No funding statement was detected.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. 

   Version published to 10.1101/2020.03.29.014407 on bioRxiv

   Mar 31, 2020